Collegium Pharmaceutical, Inc. (COLL): Price and Financial Metrics

Collegium Pharmaceutical, Inc. (COLL): $38.82

2.09 (-5.11%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

A

Add COLL to Watchlist
Sign Up

COLL Price/Volume Stats

Current price $38.82 52-week high $40.95
Prev. close $40.91 52-week low $20.83
Day low $38.59 Volume 613,200
Day high $40.95 Avg. volume 457,898
50-day MA $35.55 Dividend yield N/A
200-day MA $27.20 Market Cap 1.24B

COLL Stock Price Chart Interactive Chart >

COLL POWR Grades

  • Quality is the dimension where COLL ranks best; there it ranks ahead of 98.86% of US stocks.
  • COLL's strongest trending metric is Quality; it's been moving up over the last 26 weeks.
  • COLL ranks lowest in Momentum; there it ranks in the 6th percentile.

COLL Stock Summary

  • With a price/earnings ratio of 122.47, COLLEGIUM PHARMACEUTICAL INC P/E ratio is greater than that of about 94.98% of stocks in our set with positive earnings.
  • Over the past twelve months, COLL has reported earnings growth of -944.42%, putting it ahead of merely 1.51% of US stocks in our set.
  • Revenue growth over the past 12 months for COLLEGIUM PHARMACEUTICAL INC comes in at 51.14%, a number that bests 91.16% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to COLLEGIUM PHARMACEUTICAL INC, a group of peers worth examining would be CHEF, APG, GVA, FIGS, and PIPR.
  • COLL's SEC filings can be seen here. And to visit COLLEGIUM PHARMACEUTICAL INC's official web site, go to www.collegiumpharma.com.

COLL Valuation Summary

  • In comparison to the median Healthcare stock, COLL's price/sales ratio is 18.18% lower, now standing at 1.8.
  • COLL's price/sales ratio has moved NA NA over the prior 105 months.

Below are key valuation metrics over time for COLL.

Stock Date P/S P/B P/E EV/EBIT
COLL 2023-12-29 1.8 5.6 111.3 13.8
COLL 2023-12-28 1.8 5.6 111.4 13.8
COLL 2023-12-27 1.8 5.6 111.3 13.8
COLL 2023-12-26 1.8 5.5 109.3 13.6
COLL 2023-12-22 1.8 5.5 108.7 13.6
COLL 2023-12-21 1.8 5.6 110.2 13.7

COLL Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at 241.79%.
  • Its 4 year net income to common stockholders growth rate is now at 87.63%.
  • The 3 year net cashflow from operations growth rate now stands at -56.03%.
COLL's revenue has moved up $64,974,000 over the prior 33 months.

The table below shows COLL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 361.675 94.103 -42.837
2022-06-30 313.505 68.588 -35.248
2022-03-31 272.898 57.672 42.786
2021-12-31 276.868 103.557 71.517
2021-09-30 325.777 89.936 103.509
2021-06-30 326.11 106.862 106.749

COLL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • COLL has a Quality Grade of B, ranking ahead of 83.9% of graded US stocks.
  • COLL's asset turnover comes in at 0.493 -- ranking 87th of 681 Pharmaceutical Products stocks.
  • IBIO, IRWD, and COCP are the stocks whose asset turnover ratios are most correlated with COLL.

The table below shows COLL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.493 0.608 0.369
2021-03-31 0.498 0.612 0.422
2020-12-31 0.483 0.580 0.341
2020-09-30 0.552 0.522 0.367
2020-06-30 0.638 0.460 0.266
2020-03-31 0.772 0.391 2.336

COLL Price Target

For more insight on analysts targets of COLL, see our COLL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.71 Average Broker Recommendation 1.56 (Moderate Buy)

Collegium Pharmaceutical, Inc. (COLL) Company Bio


Collegium Pharmaceuticals is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx technology platform for the treatment of chronic pain and other diseases. The company was founded in 2002 and is based in Canton, Massachusetts.


COLL Latest News Stream


Event/Time News Detail
Loading, please wait...

COLL Latest Social Stream


Loading social stream, please wait...

View Full COLL Social Stream

Latest COLL News From Around the Web

Below are the latest news stories about COLLEGIUM PHARMACEUTICAL INC that investors may wish to consider to help them evaluate COLL as an investment opportunity.

Collegium Pharmaceutical Inc CEO Joseph Ciaffoni Sells Company Shares

On December 21, 2023, Joseph Ciaffoni, President and CEO of Collegium Pharmaceutical Inc (NASDAQ:COLL), executed a sale of 4,357 shares of the company.

Yahoo | December 23, 2023

Collegium Pharmaceutical Inc CEO Joseph Ciaffoni Sells 68,768 Shares

Joseph Ciaffoni, the President and CEO of Collegium Pharmaceutical Inc (NASDAQ:COLL), sold 68,768 shares of the company on December 20, 2023, according to a recent SEC filing.

Yahoo | December 21, 2023

Collegium Pharmaceutical (NASDAQ:COLL) ascends 8.3% this week, taking five-year gains to 77%

The main point of investing for the long term is to make money. Better yet, you'd like to see the share price move up...

Yahoo | December 14, 2023

Insider Sell: EVP and General Counsel Shirley Kuhlmann Sells 25,600 Shares of Collegium ...

Shirley Kuhlmann, the Executive Vice President and General Counsel of Collegium Pharmaceutical Inc, has recently sold 25,600 shares of the company's stock.

Yahoo | November 30, 2023

Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent

STOUGHTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the U.S. Court of Appeals for the Federal Circuit has upheld the judgment of the Patent Trial and Appeal Board (PTAB) in its final decision that Purdue’s ‘961 patent, which Purdue has claimed is infringed by Xtampza® ER, is invalid. The Federal Circuit’s decision affirming the invalidity of Purdue’s ‘961 patent confirms b

Yahoo | November 27, 2023

Read More 'COLL' Stories Here

COLL Price Returns

1-mo 6.15%
3-mo 26.12%
6-mo 73.69%
1-year 59.29%
3-year 62.84%
5-year 156.41%
YTD 26.12%
2023 32.67%
2022 24.20%
2021 -6.74%
2020 -2.67%
2019 19.86%

Continue Researching COLL

Here are a few links from around the web to help you further your research on Collegium Pharmaceutical Inc's stock as an investment opportunity:

Collegium Pharmaceutical Inc (COLL) Stock Price | Nasdaq
Collegium Pharmaceutical Inc (COLL) Stock Quote, History and News - Yahoo Finance
Collegium Pharmaceutical Inc (COLL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!